The fund, announced alongside N.B. Health Minister, Hon. Bruce Fitch, ResearchNB and the Atlantic Cancer Research Institute, is intended to support and enhance research and innovation initiatives related to cancer care in Canada. For more information on the BeiGene Canada Fund and to apply please click here.
Announcement Made in Collaboration with the New Brunswick Minister of Health, ResearchNB, and the Atlantic Cancer Research Institute. MONCTON, NB, Aug. 21, 2023 /CNW/ – BeiGene Canada, the country affiliate of global biotechnology company BeiGene, specialized in the discovery and development of novel, affordable, and accessible oncology medications, announced today the launch of a partnership […]
TORONTO, May 30, 2023 /CNW/ – BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, announced today that (PR) BRUKINSA® (zanubrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, has been granted a Notice of Compliance from Health Canada for the treatment of adult patients with chronic lymphocytic leukemia (CLL). This is the fourth Canadian approval for BRUKINSA, following authorizations for: […]
First and only BTK inhibitor to be granted provincial formulary approval TORONTO, Feb. 6, 2023 /CNW/ – BeiGene Canada, the affiliate of BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, announced today that the Government of Quebec will publicly fund BRUKINSA® (zanubrutinib), a second generation inhibitor of Bruton’s tyrosine kinase (BTK), for the treatment of adult […]
MISSISSAUGA, ON, Jan. 9, 2023 /CNW/ – BeiGene Canada, a subsidiary of global pharmaceutical company BeiGene has been recognized as a Great Place to Work® following a thorough, independent analysis conducted by the Great Place to Work® Institute Canada. BeiGene joins leading Canadian organizations whose employees have created and excelled at fostering exemplary workplaces. “We are extremely proud to have been […]
BRUKINSA is now commercially available in Canada following approval in March. Canadian patients now have access to the myBeiGene® patient support program. MISSISSAUGA, Ontario–(BUSINESS WIRE)– BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the official launch of BRUKINSA® (zanubrutinib) in Canada for the treatment of adult patients with Waldenström’s macroglobulinemia (WM). […]
